EVL:#NAME?

概要

論文の詳細を見る
We investigated a series of patients who underwent endoscopic variceal ligation (EVL) in our hospital and evaluated the clinical usefulness of EVL in comparison with that of endoscopic injection sclerotherapy (EIS) and surgery. Seventy-two patients were treated with EVL alone and 30 patients were treated with combined therapy (EVL+EIS). A pneumo-active EVL device (Sumitomo Bakelite, Tokyo, Japan) was used for ligation. Another 226 patients were treated with EIS and 156 patients were treated with surgical methods. Recurrent varices were found in 41 (40%) patients during the follow-up period. Bleeding after the therapy occurred in 10 (9.8%) patients treated with EVL, 25 (11%) with EIS and 26 (17%) with surgery. Cumulative survival rates after 1, 3 and 5 years in the patients treated by EVL were 83%, 67% and 61%, respectively. These data were comparable to those of EIS (82, 60, 45%) and surgery (81, 69, 60%). Twenty-six patients treated with EVL died during the follow-up period, and major causes of death in EVL patients were liver failure and liver cancer. In conclusion, this study suggests that EVL can be an alternative to EIS and surgery in the treatment of esophageal varices.
The Japan Society for Portal Hypertensionの論文